Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Argatroban plus endovascular standard treatment for acute ischemic stroke
ChiCTR2500095382Phase 4Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of argatroban in ischemic stroke (2 arms), sponsored by Xinqiao Hospital. Primary endpoints: Change in 90-day modified Rankin Scale score, Incidence of symptomatic intracranial hemorrhage and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
argatroban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2500095382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095382.